You:
"Looking specifically at seeing how IL2Ralpha inhibition was correlated with changes in T cells activation in patients blood 28 days after treatment - we'll they could only do that if the patients blood was taken and recording allowing them to do that - and that only occurred in the case of 25 patients."
I don't believe that statement is correct:
"Results: Biomarker data were collected in 40 subjects. At baseline, the mean age was 8.5 years, aGVHD severity by IBMTR grade C or D, median MAP was 0.369, with a MAP ≥ 0.291 in 60% of subjects, reflecting active gastrointestinal inflammation and high risk for 6-month NRM."
https://ash.confex.com/ash/2020/webprogram/Paper140899.html
25 patients or as I understood the 60% of the 40 patients (24, but 62.5% seemed close enough to me) of these subjects with a MAP ≥ 0.291, were then matched with "27 closely matched children from the Mount Sinai Acute GVHD International Consortium (MAGIC)2 who participated in a prospective natural history study" to show the survival benefit of the patient group treated with remestemcel-L vs SoC.
https://www.globenewswire.com/news-release/2021/10/18/2315632/0/en/Remestemcel-L-Improves-Survival-of-Children-With-Biomarkers-for-Highest-Mortality-in-Steroid-Refractory-Acute-GVHD.html
Or is the above simply coincidence (genuine question)?
- Forums
- ASX - By Stock
- CYP
- Ann: Investor Presentation
Ann: Investor Presentation, page-572
-
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
20.0¢ |
Change
-0.005(2.44%) |
Mkt cap ! $36.11M |
Open | High | Low | Value | Volume |
20.5¢ | 21.5¢ | 20.0¢ | $13.43K | 65.55K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 109917 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 9225 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 109917 | 0.200 |
2 | 68825 | 0.195 |
3 | 122713 | 0.190 |
3 | 65055 | 0.180 |
3 | 7139 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 9225 | 2 |
0.255 | 187726 | 1 |
0.270 | 30000 | 1 |
0.280 | 8209 | 2 |
0.285 | 60000 | 1 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online